+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group



Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group



Blood 92(12): 4560-4567



The BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, a rearranged and accelerated version of the standard COPP/adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, has been shown to be effective and safe in a previous pilot study for advanced stage Hodgkin's disease (HD). The present study aimed to determine a maximum practicable dose of three drugs, ie, etoposide, adriamycin, and cyclophosphamide, for which acute toxicities were acceptable and to assess the feasibility of the escalated scheme. Sixty untreated patients with advanced stage HD were enrolled in this study. Radiotherapy was given in 44 patients (73%) after chemotherapy to initial bulk lesions and residual disease. Granulocyte-colony stimulating factor (G-CSF) was given from day 8 to prevent prolonged neutrocytopenia and severe infections. The intended doses of adriamycin, etoposide, and cyclophosphamide in the BEACOPP schedule could be substantially escalated: adriamycin from 25 to 35, cyclophosphamide from 650 to 1,200, and etoposide from 100 to 200 mg/m2. The major toxicities were leukocytopenia and thrombocytopenia with considerable heterogeneity between individual patients. Of 60 patients, 56 (93%) achieved a complete remission (CR). At a median observation of 32 months, the rates of survival and freedom from treatment failure (FFTF) were estimated to be 91% (95% confidence interval 83% to 99%) and 90% (82% to 98%). These results show that a moderate dose escalation of adriamycin, cyclophosphamide, and etoposide of the baseline BEACOPP regimen is feasible. The escalated BEACOPP regimen shows very encouraging results in advanced stage HD and is now being compared in a randomized phase III study with BEACOPP at baseline dose level.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010996374

Download citation: RISBibTeXText

PMID: 9845521


Related references

14-azacamptothecin: a potent water-soluble topoisomerase I poison. Journal of the American Chemical Society 127(3): 838-839, 2005

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clinical Cancer Research 13(22 Pt 1): 6689-6695, 2007

Severe pulmonary stenosis and aortopulmonary fistula caused by a dissecting aneurysm in the ascending aorta. Journal of Thoracic and Cardiovascular Surgery 126(2): 598-600, 2003

Lomustine (CeeNU). Medical Letter on Drugs and Therapeutics 18(24): 102-103, 1976

Chemotherapy of highly malignant thyroid tumors. Wiener Klinische Wochenschrift 102(9): 274-276, 1990

Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 499-501, 1996

Ten years' experience with centralized surgery of ovarian cancer in one health region in Norway. International Journal of Gynecological Cancer 22(2): 226-231, 2012

Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Seminars in Arthritis and Rheumatism 40(2): 127-136, 2010

Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma. La Radiologia Medica 117(7): 1250-1263, 2012

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer 70(10): 2488-2492, 1992

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer 97(10): 2498-2503, 2003

Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. International Journal of Gynecological Cancer 5(1): 56-60, 1995

Comparison of adrenergic receptor binding in blood cells from alcoholics and controls. Alcohol 1(5): 369-372, 1984

Autotransfusion system or integrated automatic suction device in minimized extracorporeal circulation: influence on coagulation and inflammatory response. European Journal of Cardio-Thoracic Surgery 39(5): E139-E143, 2011

Prognostic factors in elderly patients with acute myeloid leukaemia: Development of a model to predict survival. British Journal of Haematology 85(2): 300-306, 1993